News

Review of the largest transactions and the most important events in the global financial markets. Detailed analytics of the trading sessions of the American stock exchange NYSE and NASDAQ

New securities on the Moscow Exchange in July 2021

New securities appear on the Moscow Exchange every month, and July was no exception. A new bond of one of the regions has appeared, many bonds of Russian companies, new shares of foreign companies, depositary receipt of a network of medical clinics and various exchange-traded funds. Part of the new bonds we do not mention.

Bundle of investment news: Shutterstock, Twitter and other reports

In this issue, we continue to analyze the reporting of companies, whose activities we covered on the site. Disclaimer: when we talk about, that something has grown, we mean a comparison with the same quarter a year earlier. Since all issuers are from the USA, then all results in dollars.

Investidea: Paymentus, because it should be more expensive

Today we have a moderately speculative idea.: take shares of the fintech company Paymentus (NYSE: PAY), in order to capitalize on the growth of these shares after a recent fall and a favorable business environment for the company. Growth potential and validity: 14% behind 15 Months; 38,5% for three years; 11% per year for 15 years.

Investidea: KnowBe4, because there are more hackers

Today we have an extremely speculative idea.: take shares of KnowBe4 (NASDAQ: KNBE), working in the field of cybersecurity, in order to capitalize on the hype in this area. Growth potential and validity: 19,5% behind 18 Months; 49% behind 5 years. Why stocks can go up: news will stimulate the growth of quotations.

Levi Strauss: The company's revenue increased by 156% for the year, shares - on 125%, financial results

Denim clothing manufacturer Levi Strauss& Co (NYSE: LEVI) published financial results for the second quarter of 2021: revenue increased by 156%, to $1.3 billion; wholesale sales increased by 167%, retail — by 141%; online sales grew by 75% and accounted for 23% of total revenue; operating and net profit rose to 106 and 65 million - against a loss of 448 and 364 million a year earlier. Sales increased relative to 2020 ... Levi Strauss's revenue grew by more than 100% in each region. The company's total sales grew 2.5 times largely due to the low base effect.: a year ago, during the quarantine, some stores had to be closed. The company notes, that a third of stores in Europe and 17% of stores worldwide remained closed during the last quarter. Now, according to the company, 92% of retail outlets are open. "We significantly exceeded our revenue expectations., adjusted gross margin and adjusted EBIT. Sales in most markets recover faster, than expected, and we are emerging from the pandemic with a sustainable and improved economy.", said the company's CFO Harmit Singh. ... But remained below the level 2019 Year Compared to 2019, Levi Strauss' total revenue fell by 3%, and in the Americas, it grew by 3%. Wholesale sales in the region added 4%, and online — 61%. Sales in Europe relative to 2019 fell by 8% largely due to closed stores. Wholesale sales increased by 4%, online sales – more than 100%. Revenue in Asia compared to 2019 fell by 12%. First of all, due to the recession in the large market of India, where a large number of COVID-19 diseases are recorded. Online sales in the region added 83%. Папины джинсы По мнению руководства Levi Strauss, во втором полугодии 2021 финансового года продажи компании вырастут на 28—29% относительно 2020 года

Levi Strauss: The company's revenue increased by 156% for the year, shares - on 125%, financial results Read more

Investidea: Advansix, because chemistry is power

Today we have a moderately speculative idea: take stock of chemical manufacturer Advansix (NYSE: ASIX), to capitalize on the growth in demand for the company's products. Growth potential and validity: 12,5% behind 14 Months.

Johnson & Johnson reported revenue and profit growth and raised its forecast for the year

The largest company in the healthcare sector Johnson & Johnson (NYSE: JNJ) published a report for the second quarter of 2021: revenue increased by 27,1%, up to $23.3 billion; operating sales excluding exchange rates increased by 23%; net profit increased by 73,1%, up to 6.3 billion; net margin increased from 19.8 to 26,9%; adjusted net income increased by 49%, up to 6.6 billion; adjusted net margin increased from 24.2 to 28,4%. By regions The company divides sales by two regions: U.S. and other countries. USA (U. S.) — 51%. Revenue increased by 24,9%, up to 11.9 billion. Other countries (International) — 49%. Revenue increased by 29,5%, up to 11.4 billion. Of them 20,9% — operating sales, 8,6% - the influence of the exchange rate. By segment The company has three operating segments: consumer goods, pharmaceuticals and medical devices. Consumer goods (Consumer Health) — 16%. Revenue increased by 13,3%, up to 3.7 billion. Consumer Healthcare Market Continues to Recover After COVID-19 Negative Impact. Increased sales of skin care products, cosmetics and over-the-counter drugs. Pharmaceutics (Pharmaceutical) — 54%. Revenue increased by 17,2%, up to 12.6 billion. Sales of drugs for the treatment of psoriasis increased, myeloma and cancer. Medical devices (Medical Devices) — 30%. Revenue increased by 62,7%, up to 7 billion. Sales in this segment grew the most. A year ago, in the midst of a pandemic, Medical centers refurbished to deal with coronavirus. Non-urgent operations postponed, so the demand for equipment fell. Now, when the number of new cases of COVID-19 infections decreased, medical facilities are returning to their daily operations. Прогноз Компания повысила свои ожидания по росту выручки и скорректированной чистой прибыли на акцию в 2021 году. Revenue: It was: 9,7—10,9%, up to 90.6-91.6 billion; Became: 10,5—11,5%, up to 91.3-92.1 billion; including vaccine: 13,5—14,5%, up to 93.8-94.6 billion. Adjusted net earnings per share: …

Johnson & Johnson reported revenue and profit growth and raised its forecast for the year Read more

Investidea: CMC Materials, because semiconductors

Today we have a moderately speculative idea.: take stock of the manufacturer of products for high-tech industries CMC Materials (NASDAQ: CCMP), in order to capitalize on the growth in demand for its products. Growth potential and validity: 15% behind 14 Months; 36% behind 3 of the year.

Scroll to Top